STOCK TITAN

NanoViricides Inc - NNVC STOCK NEWS

Welcome to our dedicated news page for NanoViricides (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on NanoViricides.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NanoViricides's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NanoViricides's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
Rhea-AI Summary
NanoViricides files Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023. The report shows a cash and cash equivalent current assets balance of approximately $9.9 Million, a decrease from $11.5 Million in December 2022. The Company entered into a License Agreement with Karveer Meditech, Pvt. Ltd., India, for the use, sale, or offer of sale in India of its two clinical test drug candidates. NV-CoV-2, the Company's lead drug candidate, is about to enter Phase Ia/Ib human clinical trials. The Company estimates it has sufficient funds to complete the trials. NV-CoV-2 is a broad-spectrum, pan-coronavirus drug for the treatment of COVID. The Company also highlights the potential of its drug candidate NV-387 to have a significantly broader spectrum of antiviral effectiveness than the coronavirus family alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
clinical trial covid-19
-
Rhea-AI Summary
NanoViricides, Inc. will be presenting at The Inaugural EF Hutton Global Conference on May 10-11, 2023 in New York City. The conference provides an opportunity for key executives to share their stories with investors and press.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.37%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.73%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.5%
Tags
conferences
NanoViricides Inc

NYSE:NNVC

NNVC Rankings

NNVC Stock Data

14.72M
11.24M
4.62%
10.3%
0.84%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Shelton

About NNVC

nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir